These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 35337133)

  • 1. Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4.
    Pandey P; Khan F; Qari HA; Upadhyay TK; Alkhateeb AF; Oves M
    Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
    Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():1956. PubMed ID: 32983126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.
    Zabeti Touchaei A; Vahidi S
    Cancer Cell Int; 2024 Mar; 24(1):102. PubMed ID: 38462628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy.
    Zhang MR; Fang LL; Guo Y; Wang Q; Li YJ; Sun HF; Xie SY; Liang Y
    Int J Nanomedicine; 2024; 19():3387-3404. PubMed ID: 38617801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential.
    Wen Y; Tang F; Tu C; Hornicek F; Duan Z; Min L
    Cancer Lett; 2022 Oct; 547():215887. PubMed ID: 35995141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies.
    Yang W; Lei C; Song S; Jing W; Jin C; Gong S; Tian H; Guo T
    Cancer Cell Int; 2021 Nov; 21(1):589. PubMed ID: 34727927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for immunotherapy in melanoma.
    Teixidó C; González-Cao M; Karachaliou N; Rosell R
    Ann Transl Med; 2015 Sep; 3(15):208. PubMed ID: 26488004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
    Saleh R; Toor SM; Khalaf S; Elkord E
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.
    Makaremi S; Asadzadeh Z; Hemmat N; Baghbanzadeh A; Sgambato A; Ghorbaninezhad F; Safarpour H; Argentiero A; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint Inhibitors in Dogs: Are We There Yet?
    Giuliano A; Pimentel PAB; Horta RS
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.